Latest news
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G - BenzingaBenzinga · Thu, 06 Aug 2026 16:27:24 GMTVERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver QuantitativeQuiver Quantitative · Mon, 27 Jul 2026 11:13:00 GMTVeraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm InternationalBioPharm International · Mon, 27 Jul 2026 07:00:00 GMTVeraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMTVERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock TitanStock Titan · Mon, 27 Jul 2026 07:00:00 GMT